Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma

NCT02207062 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT02207062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02207062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2014
Completion date
November 1, 2023
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent transformed b-cell non-hodgkin lymphoma, refractory transformed b-cell non-hodgkin lymphoma